Join this informal lunch & learn session at the White City Place to understand how biotech companies can accelerate scientific research and development through lab digitalisation, automation, and collaboration.
How biotech companies use digital tools to accelerate their R&D
Join this informal lunch & learn session at the White City Place to understand how biotech companies can accelerate scientific research and development through lab digitalisation, automation, and collaboration.
In this session you'll hear how to:
Arne Scheu, CEO & Co-founder, Liliumx
LiliumX is a spin-out of the University of Oxford. LiliumX’s Co-Founder and CEO Arne Scheu (DPhil) will introduce the company’s internal and collaborative research activities and give a brief overview over their journey of building the company to date.
Filippo Prestinoni, Associate Scientist - Tissue Engineering, and Nick Massouh, Associate Scientist, Engitix
Nahuel Villegas, Chief Scientist Office, Vivantx
Vivan Therapeutics offer a comprehensive, personal genomics-based drug screening strategy for individuals with cancer. They support patients and their clinicians by identifying ultra-personalised therapeutic solutions, while also powering biopharma in drug discovery and development programs. For each patient, a genetically matched fruit fly avatar-model is built, recreating all the genetic alterations identified in the patient tumour by WES. Then, an avatar army 500,000 strong is used for large-scale drug screening to find novel and effective drug combinations. In this way, Vivan leverages patient’s genomic information, tailoring treatments to unique genetic signatures allowing at the same time an unprecedented level of stratification for clinical trials.
Reimagining Collaboration - Building effective strategies to accelerate time to market
Learn how modern biotechnology companies are using connected software to evolve their R&D approach and improve collaboration to produce more efficiently.
Advancing the Science - Approaches for working with cell and gene therapies, biologics, RNA, and emerging modalities
In this roundtable, learn how emerging biotherapeutic modalities are evolving and changing the landscape of treatments available to tackle diseases and better serve patients.
In need of more hands-on support, or a solution that connects multiple labs? Check out our paid subscriptions.
Start free trial
